keyword
MENU ▼
Read by QxMD icon Read
search

eribulin

keyword
https://www.readbyqxmd.com/read/28087961/treatment-of-heavily-pre-treated-metastatic-breast-cancer-with-eribulin-first-local-experience-in-sabah
#1
D W Lee, D C Teoh, F L Chong
There are many options in the treatment of heavily pretreated metastatic breast cancer however none of the therapeutic agents have shown promising improvement of survival with good toxicity profile. Eribulin is a novel nontaxane microtubule dynamics inhibitor. Two recent clinical trial showed that Eribulin improves progression-free and overall survival in this subset of patients. We report our experience with using Eribulin in five patients with metastatic breast cancer either in second or third-line setting, in our centre...
December 2016: Medical Journal of Malaysia
https://www.readbyqxmd.com/read/28056739/from-natural-products-to-designer-drugs-development-and-molecular-mechanisms-of-action-of-novel-anti-microtubule-breast-cancer-therapeutics
#2
Tejashree Mahaddalkar, Manu Lopus
Microtubule-targeted drugs (MTDs) have been on the forefront of breast cancer chemotherapy. Classic MTDs, such as paclitaxel and their semisynthetic derivatives, have achieved considerable success in the clinical management of breast neoplasms. In order to improve the specificity and to reduce undesirable, dose-limiting toxicities of these drugs, a plethora of novel compounds are being synthesized and investigated in laboratories worldwide. Due to their crucial roles during cell division, and to the fact that the suppression of their innate 'dynamic instability' can arrest cell cycle progression, microtubules formed an attractive target for cancer chemotherapy...
4, 2017: Current Topics in Medicinal Chemistry
https://www.readbyqxmd.com/read/28056400/efficacy-and-safety-of-eribulin-as-first-to-third-line-treatment-in-patients-with-advanced-or-metastatic-breast-cancer-previously-treated-with-anthracyclines-and-taxanes
#3
Shigeto Maeda, Michiyo Saimura, Shigeki Minami, Kaname Kurashita, Reiki Nishimura, Yuichiro Kai, Hiroshi Yano, Kohjiro Mashino, Shoshu Mitsuyama, Mototsugu Shimokawa, Kazuo Tamura
OBJECTIVES: Despite the survival benefit and acceptable tolerability of eribulin for advanced/metastatic breast cancer (MBC) patients pretreated with anthracyclines and taxanes, there is limited evidence of the clinical benefit of early eribulin use. We investigated the efficacy and safety of first- to third-line eribulin use in patients with MBC. MATERIALS AND METHODS: In this phase II, open-label, single-arm study conducted at 14 sites in Kyushu, Japan, women with histologically confirmed human epidermal growth factor receptor 2-negative MBC were enrolled between December 1, 2011 and November 30, 2013 (Data cut-off: November 30, 2014)...
January 2, 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/28028262/-maintenance-of-long-term-stable-disease-sd-in-metastatic-breast-cancer-with-eribulin-a-case-report-of-long-term-sd-in-japan
#4
Toshikatsu Nitta, Kousei Kimura, Tomo Tominaga, Kensuke Fujii, Nayuko Sato, Ayana Ikari, Kazuhiro Miyoshi, Satoru Tanaka, Takashi Ishibashi, Mitsuhiko Iwamoto
This case report discusses a 48-year-old woman with metastatic breast cancer: T4c(10.5 cm)N2bM1,(OSS, LYM), stage IV, estrogen receptor(ER)(+), progesterone receptor(PgR)(+), human epidermal growth factor receptor-2(HER2) (-), and Ki-67 17.2%. Administration of eribulin was initiated after treatment with anthracycline and taxane. Thereafter, 28 courses of eribulin maintained a SD state for over a year and improved the quality of life(QOL). Eribulin is effective for both prolonging life and improving QOL, which are the main goals in the treatment of metastatic or recurrent cancer...
December 2016: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/28028256/-treatment-continuation-and-safety-of-eribulin-for-the-treatment-of-metastatic-breast-cancer
#5
Shino Adachi, Eiseki Usami, Kazutomo Okada, Mina Iwai, Hiroki Asano, Daisuke Ito, Keitaro Kamei, Tomoaki Yoshimura
The purpose of treatment for patients with metastatic breast cancer is to maintain the patient's quality of life(QOL)with continued treatment for as long as possible.Eribulin was approved in April 2011 for the treatment of metastatic breast cancer, further increasing the selection of therapies available for the management of this disease.The current study presents a retrospective review of 31 patients who received eribulin in our hospital, and analyzes the factors related to the continuation and safety of its use...
December 2016: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/27994483/clinical-effects-of-prior-trastuzumab-on-combination-eribulin-mesylate-plus-trastuzumab-as-first-line-treatment-for-human-epidermal-growth-factor-receptor-2-positive-locally-recurrent-or-metastatic-breast-cancer-results-from-a-phase-ii-single-arm-multicenter
#6
Shannon Puhalla, Sharon Wilks, Adam M Brufsky, Joyce O'Shaughnessy, Lee S Schwartzberg, Erhan Berrak, James Song, Linda Vahdat
Eribulin mesylate, a novel nontaxane microtubule dynamics inhibitor in the halichondrin class of antineoplastic drugs, is indicated for the treatment of patients with metastatic breast cancer who previously received ≥2 chemotherapy regimens in the metastatic setting. Primary data from a Phase II trial for the first-line combination of eribulin plus trastuzumab in human epidermal growth factor receptor 2 positive patients showed a 71% objective response rate and tolerability consistent with the known profile of these agents...
2016: Breast Cancer: Targets and Therapy
https://www.readbyqxmd.com/read/27936750/extension-of-pd-mediated-one-pot-ketone-synthesis-to-macrocyclization-application-to-a-new-convergent-synthesis-of-eribulin
#7
Jung Hwa Lee, Zhanjie Li, Ayumi Osawa, Yoshito Kishi
Recently reported Pd-mediated one-pot ketone synthesis from an unactivated alkyl bromide and a thioester has been extended to a macrocyclic ketone synthesis. In situ generation of alkylzinc halide via single electron transfer (SET), using NbCpCl4 and CrCl3, was the key for the success of macrocyclization. A new convergent synthesis of eribulin has been achieved, using (1) catalytic asymmetric Ni/Cr-mediated coupling to form the C19-C20 bond, (2) base-induced cyclization to form the methylenetetrahydrofuran ring, and (3) Pd-mediated one-pot ketone synthesis to form the macrocyclic ketone...
December 21, 2016: Journal of the American Chemical Society
https://www.readbyqxmd.com/read/27918490/activity-of-eribulin-in-a-primary-culture-of-well-differentiated-dedifferentiated-adipocytic-sarcoma
#8
Alessandro De Vita, Giacomo Miserocchi, Federica Recine, Laura Mercatali, Federica Pieri, Laura Medri, Alberto Bongiovanni, Davide Cavaliere, Chiara Liverani, Chiara Spadazzi, Dino Amadori, Toni Ibrahim
Eribulin mesylate is a novel, non-taxane, synthetic microtubule inhibitor showing antitumor activity in a wide range of tumors including soft tissue sarcomas (STS). Eribulin has been recently approved for the treatment of metastatic liposarcoma (LPS) patients previously treated with anthracyclines. This work investigated the mechanism of action of this innovative antitubulin agent in well-differentiated/dedifferentiated LPS (ALT/DDLPS) which represents one of the most common adipocytic sarcoma histotypes. A primary culture of ALT/DDLPS from a 54-year-old patient was established...
December 3, 2016: Molecules: a Journal of Synthetic Chemistry and Natural Product Chemistry
https://www.readbyqxmd.com/read/27918201/the-importance-of-treating-by-histological-subtype-in-advanced-soft-tissue-sarcoma
#9
Javier Martín Broto, Axel Le Cesne, Peter Reichardt
While surgical resection (±radiotherapy) is standard treatment for localized soft tissue sarcomas (STS), chemotherapy is the mainstay for managing locally advanced and metastatic disease. Expanding knowledge of the biologies and sensitivities of STS histotypes, in conjunction with results from a growing collection of retrospective reviews and prospective randomized studies, point to the importance of treating in consideration of histological subtype. Doxorubicin ± ifosfamide continues to be standard first-line therapy for most STS subtypes...
January 2017: Future Oncology
https://www.readbyqxmd.com/read/27908980/phase-2-study-of-eribulin-in-patients-with-previously-treated-advanced-or-metastatic-soft-tissue-sarcoma
#10
Akira Kawai, Nobuhito Araki, Yoichi Naito, Toshifumi Ozaki, Hideshi Sugiura, Yasuo Yazawa, Hideo Morioka, Akihiko Matsumine, Kenichi Saito, Shun Asami, Kazuo Isu
OBJECTIVE: Eribulin, a microtubule dynamics inhibitor, is approved for the treatment of patients with breast cancer and soft tissue sarcoma. We investigated the efficacy and safety of eribulin in Japanese patients with soft tissue sarcoma. METHODS: This open-label, multicenter, nonrandomized, Phase 2 study enrolled Japanese patients with measurable, advanced/metastatic soft tissue sarcoma of high/intermediate grade and ≥1 prior chemotherapy for advanced disease...
December 1, 2016: Japanese Journal of Clinical Oncology
https://www.readbyqxmd.com/read/27904013/clinical-benefit-of-eribulin-halaven-%C3%A2-in-the-treatment-of-advanced-soft-tissue-sarcoma-patients-and-the-novel-anti-tumor-mechanisms
#11
Noriyuki Koyama, Shigeru Taniguchi, Kotaro Kodama, Osamu Tohyama, Hiroki Hasegawa, Taro Semba
No abstract text is available yet for this article.
2016: Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica
https://www.readbyqxmd.com/read/27863409/integrating-mechanisms-of-response-and-resistance-against-the-tubulin-binding-agent-eribulin-in-preclinical-models-of-osteosarcoma
#12
Valerie B Sampson, Nancy S Vetter, Wendong Zhang, Pratima U Patil, Robert W Mason, Erika George, Richard Gorlick, E A Kolb
Osteosarcoma is the most frequently occurring bone cancer in children and adolescents. Unfortunately, treatment failures are common. Eribulin is a synthetic microtubule inhibitor that has demonstrated activity in preclinical osteosarcoma models. The effects of eribulin were evaluated in two human osteosarcoma cell lines as well as in eribulin-sensitive and -resistant osteosarcoma xenograft tumors of the Pediatric Preclinical Testing Program (PPTP) by characterizing cell viability, microtubule destabilization, mitotic arrest and mechanism of cell death...
November 15, 2016: Oncotarget
https://www.readbyqxmd.com/read/27805627/breast-cancer-eribulin-effective-against-male-breast-cancer
#13
Peter Sidaway
No abstract text is available yet for this article.
January 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/27793935/antitumor-effects-of-eribulin-mesylate-in-gemcitabine-resistant-pancreatic-cancer-cell-lines
#14
Yuka Takezaki, Tsutomu Namikawa, Tsuyoshi Koyama, Eri Munekage, Masaya Munekage, Hiromichi Maeda, Hiroyuki Kitagawa, Kazuhiro Hanazaki
BACKGROUND/AIM: One reason of poor survival rate of patients with pancreatic cancer is the development of chemoresistance. The aim of the present study was to investigate the effects of eribulin mesylate in gemcitabine-refractory advanced pancreatic cancer cell lines. MATERIALS AND METHODS: Three human pancreatic cancer cell lines (AsPC-1, Panc-1, and SUIT-2) and human pancreatic endoderm (hPE) cells were used to evaluate the antitumor effects of gemcitabine and eribulin mesylate...
2016: Anticancer Research
https://www.readbyqxmd.com/read/27779690/eribulin-sensitizes-oral-squamous-cell-carcinoma-cells-to-cetuximab-via-induction-of-mesenchymal-to-epithelial-transition
#15
Hiroko Kitahara, Mariko Hirai, Koroku Kato, George Bou-Gharios, Hiroyuki Nakamura, Shuichi Kawashiri
Inhibition of epidermal growth factor receptor (EGFR) signalling has emerged as a new treatment strategy for oral squamous cell carcinoma (OSCC). Previously, we found that loss of EGFR expression in OSCC was associated with epithelial-mesenchymal transition (EMT), and may have functional implications with regard to resistance to cetuximab, a monoclonal anti-EGFR antibody. Eribulin (a microtubule inhibitor) reportedly renders breast cancer less aggressive, and less likely to metastasise, by triggering mesenchymal‑to‑epithelial (MET) transition...
December 2016: Oncology Reports
https://www.readbyqxmd.com/read/27760949/-study-of-the-relationship-between-obesity-and-lymphocytes-in-breast-cancer-patients-undergoing-chemotherapy
#16
Keita Adachi, Shuhei Suzuki, Yuki Masuo, Saki Nagashima, Yukiko Hara, Tomohiro Hirano, Katsuhisa Enomoto, Kenichi Sakurai
Obesitychanges the regulatorymechanisms of the immune system, resulting in impaired immunity. In cancer immune mechanisms, the greater the degree of obesity, the lower the activity of the lymphocytes. Herein, we examined the relationship between obesity and lymphocytes in breast cancer patients undergoing chemotherapy. We recruited 10 recurrent or metastatic breast cancer patients who were administered eribulin. Using bodymass index(BMI), we classified these patients into a non-obese group(BMI<25)and an obese group(BMI>25)...
October 2016: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/27760942/-ethinylestradiol-following-everolimus-plus-exemestane-was-effective-in-postmenopausal-endocrine-responsive-metastatic-breast-cancer-a-case-report
#17
Aya Matsuoka, Akira Hirano, Akinori Hattori, Kaoru Ogura, Hiroaki Inoue, Hiroko Yukawa, Shiho Sakaguchi, Natsuko Tanaka, Asaka Kodera, Mari Kamimura, Yoshihiko Naritaka, Tadao Shimizu
A 71-year-old woman diagnosed with left breast cancer underwent mastectomy and axillary dissection in 1987. Pathological findings showed invasive ductal carcinoma that was ER and PgR positive and HER2 negative.5 -FU and tamoxifen were administered for 2 years as adjuvant therapy.Bone metastasis was found in 2002, and endocrine therapy was started, using anastrozole, exemestane, letrozole, medroxyprogesterone acetate, and fulvestrant.However, liver, lung, pleural, penetiral, and lymph-node metastases were observed, and the following chemotherapy regimen was administered: CAF, capecitabine, paclitaxel, vinorelbine, gemcitabine, methotrexate plus mitomycin C, and eribulin...
October 2016: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/27746162/diminished-dyrk2-sensitizes-hormone-receptor-positive-breast-cancer-to-everolimus-by-the-escape-from-degrading-mtor
#18
Rei Mimoto, Naoe T Nihira, Shinichi Hirooka, Hiroshi Takeyama, Kiyotsugu Yoshida
Mammalian target of rapamycin (mTOR) inhibitor, everolimus, provides benefit for metastatic hormone receptor positive breast cancer after failure of the endocrine therapy. The present report highlights Dual Specificity Tyrosine Phosphorylation Regulated Kinase 2 (DYRK2) as a predictive marker for everolimus sensitivity. The key node and KEGG pathway analyses revealed that mTORC1 pathway is activated in DYRK2-depleted cells. Everolimus was more effective in DYRK2-depleted cells compared with control cells. In xenograft model, everolimus treatment significantly inhibited tumor growth compared with vehicle or eribulin treatment...
October 13, 2016: Cancer Letters
https://www.readbyqxmd.com/read/27742906/eribulin-in-male-patients-with-breast-cancer-the-first-report-of-clinical-outcomes
#19
Francesco Giotta, Luigi Acito, Giampiero Candeloro, Pietro Del Medico, Gennaro Gadaleta-Caldarola, Guido Giordano, Rossana Gueli, Antonio Lugini, Valentina Magri, Marta Mandarà, Giovanna Masci, Salvatore Pisconti, Mirco Pistelli, Anna Rizzi, Nello Salesi, Alessio Schirone, Giovanni Scognamiglio, Maria Tedeschi, Patrizia Zucchinelli
BACKGROUND: Evidence on the management and treatment of male breast cancer is scant. We report the analysis of a multicenter Italian series of patients with male breast cancer treated with eribulin. To our knowledge, this is the first report on the use or eribulin in this setting. PATIENTS AND METHODS: Patients were retrospectively identified in 19 reference centers. All patients received eribulin treatment, according to the standard practice of each center. Data on the identified patients were collected using a standardized form and were then centrally reviewed by two experienced oncologists...
October 14, 2016: Oncologist
https://www.readbyqxmd.com/read/27721762/combination-chemotherapy-of-mitomycin-c-and-methotrexate-was-effective-on-metastatic-breast-cancer-resistant-to-eribulin-vinorelbine-and-bevacizumab-after-anthracycline-taxane-and-capecitabine
#20
Masahiko Tanabe
Complete cure of metastatic breast cancer (MBC) is still considered difficult even after the development of new drugs. While new drugs have been continuously developed, conventional drugs such as mitomycin C (MMC) and methotrexate (MTX) have become less used. Combination chemotherapy with MMC and MTX (MMC/MTX) was reported to be effective for 9.7-19.4% of 31 patients with human epidermal growth factor receptor type 2 (HER2)-negative MBC who were aggressively treated with anthracycline, taxane, capecitabine, and vinorelbine...
May 2016: Case Reports in Oncology
keyword
keyword
95636
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"